BSX Shareholders - Lead Plaintiff Deadline: May 04, 2026

Boston Scientific Corporation Class Action Lawsuit – BSX

Introduction to Boston Scientific Corporation (BSX) Securities Class Action Lawsuit

A securities fraud class action has been filed against Boston Scientific Corporation (NYSE: BSX) and several of its executives for alleged violations of federal securities laws between July 23, 2025, and February 3, 2026. Investors allege that defendants made materially false and misleading statements about the company's Electrophysiology business segment (EP), including its Farapulse pulsed field ablation platform, specifically claiming sustained high growth rates, competitive strength, and confidence in future performance while concealing deteriorating market conditions, unsustainable growth trajectories, and intensifying competitive pressures. On February 4, 2026, Boston Scientific Corporation revealed disappointing U.S. EP sales results in an earnings disclosure and issued fiscal 2026 guidance that fell well below expectations, attributing the shortfall to slower market growth and increased competition. The company's stock price plummeted $16.12 per share, a 17.6% decline in a single day, for BSX shareholders, as the truth emerged.

Boston Scientific Corporation (BSX) Securities Lawsuit Case Details

Case Name: John Rudolph Troike v. Boston Scientific Corporation, et al.

Case No.: 4:26-cv-40075

Jurisdiction: U.S. District Court, District of Massachusetts

Filed on: March 5, 2026

Boston Scientific Corporation (BSX) Company Profile

Boston Scientific Corporation is a global company headquartered in Marlborough, Massachusetts that develops, manufactures, and markets medical devices used across various specialties, and is publicly traded on the NYSE (ticker: BSX). The company's Electrophysiology business unit develops and manufactures products used in the detection and treatment of heart rate and rhythm disorders, including cardiac rhythm management, with the Farapulse PFA system as its key product offering, a pulsed field ablation technology within cardiovascular and electrophysiology medicine.

Boston Scientific Corporation (BSX) Securities Lawsuit Class Period

July 23, 2025 – February 3, 2026, inclusive.

Investors who purchased or otherwise acquired Boston Scientific Corporation common stock during the Class Period may be eligible to join the Boston Scientific Corporation (BSX) class action lawsuit.

Allegations in the Boston Scientific Corporation (BSX) Securities Class Action Lawsuit

Investors allege that Boston Scientific Corporation and five of its executives, in this federal securities class action-Chairman and CEO Michael F. Mahoney, CFO Jonathan R. Monson, Chief Medical Officer Kenneth M. Stein, Executive Vice President of Cardiology Joseph M. Fitzgerald, and Global President of Electrophysiology Nicholas Spadea-Anello-made materially false and misleading statements about the company's growth prospects and competitive position for its U.S. Electrophysiology (EP) segment. On July 23, 2025, Mahoney announced in a press release that the quarter delivered "exceptional top-line performance" and positioned the company for "differentiated long-term performance.” During the earnings call, he stated that the company expected "continued high single-digit growth led by our proprietary technologies" in the second half of the year , including the Farapulse PFA platform. On September 30, 2025, at the company's Analyst/Investor Day Conference, Fitzgerald characterized the EP market as "the largest in medtech and the fastest growing in medtech" within cardiovascular medicine, projecting that the EP market would grow at 15% over the long-range plan and that the Company would "outpace the market." On December 2, 2025, at the Citi Annual Global Healthcare Conference, Fitzgerald assured investors that the company had "a very good understanding of what competition we will face and in what time frame" in the U.S. EP market.

According to the complaint, defendants provided these overwhelmingly positive statements while concealing material adverse facts about the true state of Boston Scientific Corporation's U.S. EP segment and the sustainability of EP revenue growth. Management allegedly knew that the segment's growth rate was unsustainable in U.S. procedures and that it was approaching an earlier tipping point than the market was anticipating. The complaint alleges that defendants failed to disclose material adverse trends affecting procedure volumes, competitive pressures, and regulatory and reimbursement headwinds for the EP segment that would ultimately necessitate lowered expectations. Due to defendants' statements of confidence and lofty expectations, analysts were left surprised by Boston Scientific Corporation's net income miss and underwhelming guidance for the first half of fiscal 2026 for investors in BSX common stock.

The Truth Emerges

On February 4, 2026, Boston Scientific Corporation published a press release and accompanying earnings disclosure announcing fourth quarter and full year 2025 results that included a significant disappointment in U.S. EP sales and issued guidance for fiscal 2026 that fell well below expectations reflecting a slower EP market outlook. The company attributed its results and dismal guidance to a combination of slower than expected market growth alongside increased competition in pulsed field ablation. During the earnings call, Mahoney stated that the EP market in the fourth quarter "was closer to 18% to 20% growth rather than what some other companies have claimed at 25%," calling the market for 2026 "about 15% growth." He also acknowledged that "with new entrants coming, it's not surprising that we lost some share" in U.S. electrophysiology.

These revelations directly contradicted management's previous claims of a growing EP business and assertions that they had "a very good understanding of what competition we will face and in what time frame" from prior investor presentations and conferences. The disappointing results and lowered guidance exposed that the growth trajectory and competitive strength defendants had repeatedly touted throughout the class period were not sustainable according to the complaint.

Market Reaction

Investors and analysts reacted immediately to the corrective disclosures following Boston Scientific Corporation's revelation. From a closing market price of $91.62 per share on February 3, 2026, for NYSE: BSX common stock, Boston Scientific Corporation's stock price fell to $75.50 per share on February 4, 2026, a decline of about 17.6% in the span of just a single day, reflecting a significant stock price decline linked to the EP guidance.

Next Steps

●      The Court will issue its order for lead plaintiff and counsel in the weeks after submissions are due.

●      The Court will then consider motion for class certification.

●      The Court will later consider a Motion to Dismiss.

Disclaimer: This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. No specific outcomes are guaranteed.

Additional Information

Add Your Transactions

Purchases

+ Additional Purchases

Sales

+ Additional Sales

Alternatively, you may upload your transactions below or e-mail them to [email protected]

Certification of Plaintiff Pursuant to Federal Securities Laws

I, duly certify and say, as to the claims asserted under the federal securities laws, that:

  1. I have reviewed a complaint filed in the action.
  2. I did not purchase the security that is the subject of this action at the direction of plaintiff's counsel or in order to participate in this action.
  3. I am willing to serve as a representative party on behalf of the class, including providing testimony at deposition and trial, if necessary.
  4. My transaction(s) in Boston Scientific Corporation which are the subject of this litigation during the class period set forth in the complaint are set forth in the chart attached hereto.
  5. Within the last 3 years,
  6. I will not accept any payment for serving as a representative party on behalf of the class beyond the Plaintiff's pro rata share of any recovery, except as ordered or approved by the court, including any award for reasonable costs and expenses (including lost wages) directly relating to the representation of the class.

Are you US Citizen?

Clear

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

By your signature above, you confirm that have retained Levi & Korsinsky, LLP to represent you and the shareholder class as a lead plaintiff in the pending class action against Boston Scientific Corporation. This representation will be on a contingency basis, meaning that Levi & Korsinsky will advance all expenses in the litigation and will only seek compensation and/or reimbursement of expenses if the firm obtains a recovery. Regardless of the result, we will never ask you to directly pay for any attorneys’ fees, expenses, or costs. Should we obtain a favorable result, we may ask the court to award us compensation and reimbursement of expenses to be paid by the defendants or as a portion of any class recovery. In exchange for our representation, you agree to cooperate as our client by providing, for example, relevant documents and deposition testimony, if necessary. During the course of this litigation, we may employ and/or work with other law firms, experts, and third-parties to successfully prosecute this action. If you are not appointed as the lead plaintiff or Levi & Korsinsky is not appointed as lead counsel, we will notify you of such decision at which time this representation will end unless otherwise extended by you and the firm. We look forward to working with you towards a successful resolution of this action.

Upload Your Stock Tickers

Tell us the stocks you own using SnapTrade, and we will keep you informed about class action litigation related to your stocks.

We monitor critical case developments that may affect the price of your shares and your possible monetary recovery.

SnapTrade only shares the tickers you own and your transaction history — not your account numbers. Using SnapTrade and participating in our monitoring service is free and does not create an attorney-client relationship or obligation on your part.

Don’t miss out on possible monetary recovery — link your brokerage account with SnapTrade.